Displaying 71 - 80 of 243
Alternative Name: Casea S
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
Development Phase: Limited Market Availability

Pages

Displaying 61 - 70 of 70
User: Female
Hormonal: No
Developer: Rutgers University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Target
User: Male
Hormonal: No
Developer: Baylor College of Medicine, NICHD
Development Stage: Target Validation
Alternative Name: RISUG in the Fallopian Tube
User: Female
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Fallopian Tube
Developer: Indian Institute of Technology, Kharagpur
Development Stage: Prototype Development
Alternative Name: Tripterygium wilfordii derivatives, including triptolide
User: Male
Hormonal: No
Developer: WHO, University of California at Los Angeles
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: FHI 360, GE Healthcare
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Delivery Method: Vaginal, Other
Developer: University of Texas Health Science Center at San Antonio
Development Stage: Lead Optimization
Alternative Name: WEE1 HOMOLOG 2; WEE1B; WEE2 Kinase
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Lead Optimization
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization

Pages

Displaying 31 - 40 of 121
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Alternative Name: Single Rod GES Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Phase III
Alternative Name: GES VR
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Pre-clinical

Pages

Displaying 41 - 50 of 52
Alternative Name: MCR-165, Medicated Contraceptive Ring-165
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed
Alternative Name: Depo-subQ + Uniject
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Pfizer, PATH, USAID
Development Stage: SRA/WHO PQ Approved
Alternative Name: Flomax
User: Male
Hormonal: No
Duration Type: Pericoital
Delivery Method: Oral
Development Stage: SRA/WHO PQ Approved
Alternative Name: IUD HBCu375/MCu375 and TCu380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tianjin Medical Instrument Factory
Development Stage: Marketed
Alternative Name: Triclovera; OSKB -1
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: PT. Tunggal Idaman Abdi
Development Stage: Marketed
Alternative Name: LNG Contraceptive IUS 12 (LCS12)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council, Theramex, Rockefeller Foundation
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Development Stage: Marketed
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed

Pages

CSV